DHI Stock Estimates Surpass as Orders Rise 11% in Weak Housing Market

As the most active home builder in the United States, DR Horton NYSE: DHI is facing a general market downturn in new home sales and savvy buyers.

However, investors may not know that in its financial performance. In the most recent quarter, the company beat expectations, raised its revenue outlook, increased orders for new homes by double digits, and returned more than $1 billion to shareholders.

That is not to suggest that the company is immune to industrial shocks. Analysts rate the stock as Hold with limited upside for 12 months.

But for patient investors, the disconnect between the home buyer's compromise and the company's bottom line is something to consider before deciding to take action.

Building Its Business Around Affordable Homes

DR Horton has been building homes for Americans since 1978, and during those decades has become the largest homebuilder in the United States by volume, with operations spanning 125 markets in 35 states.

Its strategic focus on entry-level and first-time homebuyers gives it protection against the luxury home trend. When mortgage rates are rising, and smart buyers are backing off, low-priced starter homes tend to hold up the longest.

Like other homebuilders in the construction sector, sales began in late 2020 as interest rates remained low and working from home attracted more buyers to the market. But that was not the latest story. Monthly new home sales have fallen nearly 30% since that peak and are currently at their lowest levels since 2023.

Strong Quarterly Results Defy Weak Housing Market

The current trend is what makes DR Horton's second fiscal quarter ending March 31 so interesting. It was the latest clear evidence of what the company produces under pressure.

The company reported that in three months, it generated 7.6 billion dollars in revenue, more than expected by analysts, and 647.9 million dollars in income, or $2.24 per diluted share. Its average pre-tax profit margin was 11.5%.

While exceeding expectations, income for the period was down slightly from year-ago levels as housing prices and grants reflected higher loan levels. “Affordability issues and cautious consumer sentiment continue to impact the search for a new home,” the company said.

The basic need, however, was undoubtedly correct. Total sales orders increased 11% to 24,992 homes, with an order value of $9.2 billion. The backlog grew to 16,882 homes worth $6.4 billion at the end of the quarter. With orders and possible backlog indicators of sales moving forward, both are moving in the right direction.

Orders and Inventory Point to Future Power

And the details inside the numbers mean. Home foreclosures in the quarter rose 1% to 19,486 as income in the homebuilding sector, hit by consumer complaints, fell 2% to $7.1 billion.

The company also raised nearly $800 million in cash during the quarter from leasing activities, financial services, and the sale of prime real estate to homebuilders.

The inventory is also improved. Unfinished homes for sale are down 35% from last year. And the cancellation rate remains low at 16%, in line with previous times and well below levels that would indicate consumer panic.

Given these figures, the company revised its full-year revenue guidance to a range of $33.5 billion to $34.5 billion for the number of homes sold between 86,000 and 87,500, a view that came in above analyst expectations even after the range was narrowed. By comparison, in fiscal 2025, the company sold 84,863 homes, a 5% decrease.

Shareholder Returns Reflect Financial Confidence

These days, the stock reflects a recognition of the company's performance without being optimistic about its near-term prospects. DHI recently traded near $159, up 12% over the past three months. The trailing price ratio of 14.7 is slightly higher than others in the sector.

In the second quarter alone, DR Horton repurchased 6 million shares for $950.6 million and paid out $130 million in dividends, coming out of the period with net cash of $6 billion and net debt of 21.7%.

After the end of the quarter, the board also declared another quarterly dividend of R45 cents per share, making a positive yield of 1.1%. The company also confirmed plans for $2.5 billion in share repurchases and about $500 million in dividend payments for fiscal 2026.

Analysts Expect Only Limited Near-Term Coverage

The analyst's hearing is moderate rather than over-enthusiastic. Out of 16 analysts following the stock, the consensus rating is Hold, with four recommending Buy, 10 suggesting Hold, and two writing it as Sell.

With an average price target of $168.54, the 12-month target suggests an upside of about 6%. Much of the industry has already enjoyed a brief rally following the congressional passage of the affordable housing bill, a reminder of just how serious the issues can be.

House Storms Still Have Reasonable Risks

The bear case is easily identified, and the reason the stock is priced the way it is. Affordability remains a key issue driving new home demand.

Sales profits are expected to remain high through fiscal 2026, thereby reducing margins and limiting earnings. As seen in the second quarter, the income from real estate sales decreased as the seal closed.

The competitive environment adds to the anxiety. Among the homebuilders, Lennar NYSE: LEN targets the same consumers, while PulteGroup NYSE: PHMNVR NYSE: NVRand Toll Brothers NYSE: TOL target very different segments.

In addition, the existing home market can loosen and attract buyers if mortgage rates fall.

Quality Builder in an Uncertain Market

For investors, the question is whether we should treat DR Horton as part of the innovative homebuilding industry or as a high-quality property manufacturer. With its ability to generate cash, maintain a clean balance sheet, and return capital to shareholders, the company has proven to be able to withstand cycles.

But the great nature is difficult to predict. A continued economic downturn and high unemployment could further strain consumer budgets and reduce home sales. The future of interest rates is the deciding factor.

Either way, DR Horton has earned the right to be taken seriously even in a market that has yet to decide what to do with it.

Before you consider DR Horton, you'll want to hear this.

MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and DR Horton wasn't on the list.

Although DR Horton currently has a hold rating among analysts, senior analysts believe these five stocks are better buys.

View Five Stocks Here

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report